BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,145 | +62.6% | 2,357 | +6.0% | 0.00% | – |
| Q2 2023 | $38,230 | +12.8% | 2,223 | +8.7% | 0.00% | – |
| Q1 2023 | $33,903 | +160.8% | 2,045 | +13.0% | 0.00% | – |
| Q4 2022 | $13,000 | -27.8% | 1,810 | -2.4% | 0.00% | – |
| Q3 2022 | $18,000 | 0.0% | 1,855 | -4.4% | 0.00% | – |
| Q2 2022 | $18,000 | 0.0% | 1,941 | +7.3% | 0.00% | – |
| Q1 2022 | $18,000 | -35.7% | 1,809 | +4.8% | 0.00% | – |
| Q4 2021 | $28,000 | -70.2% | 1,726 | -14.0% | 0.00% | – |
| Q3 2021 | $94,000 | -23.0% | 2,007 | 0.0% | 0.00% | – |
| Q2 2021 | $122,000 | +19.6% | 2,007 | +20.5% | 0.00% | – |
| Q1 2021 | $102,000 | -19.7% | 1,666 | -6.8% | 0.00% | – |
| Q4 2020 | $127,000 | +159.2% | 1,788 | +37.0% | 0.00% | – |
| Q3 2020 | $49,000 | +14.0% | 1,305 | 0.0% | 0.00% | – |
| Q2 2020 | $43,000 | +79.2% | 1,305 | +57.2% | 0.00% | – |
| Q1 2020 | $24,000 | – | 830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |